Novel tumor necrosis factor toxic effects. Pulmonary hemorrhage and severe hepatic dysfunction.
Recombinant human tumor necrosis factor is an investigational antitumor agent currently undergoing clinical trials. Previous reports of pulmonary and hepatic toxicities include mild reversible decline in pulmonary diffusing capacity and mild elevation of bilirubin and transaminases. This report describes two novel toxicities in patients receiving their first intravenous dose of tumor necrosis factor: pulmonary hemorrhage and severe hepatic dysfunction. These patients received no other antitumor therapy for at least 4 weeks before tumor necrosis factor treatment and no additional antitumor therapy concomitant with tumor necrosis factor. An analysis of the possible pathogenesis is presented.
Schilling
P J
PJ
University of Texas M.D. Anderson Cancer Center, Houston 77030.
Murray
J L
JL
Markowitz
A B
AB
D000328:Adult; D001943:Breast Neoplasms / Q000188:drug therapy; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000188:drug therapy / Q000556:secondary; D056486:Chemical and Drug Induced Liver Injury; D004341:Drug Evaluation; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary; D014409:Tumor Necrosis Factor-alpha / Q000009:adverse effects* / Q000627:therapeutic use
D014409:Tumor Necrosis Factor-alpha